AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
25 Feb, 20:00
NYSE NYSE
$
226. 92
-1.52
-0.67%
$
397.32B Market Cap
42.2 P/E Ratio
1.63% Div Yield
3,817,638 Volume
10.28 Eps
$ 228.44
Previous Close
Day Range
226.47 232.55
Year Range
164.39 244.81
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABBV earnings report is expected in 56 days (23 Apr 2026)
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings

Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings

Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.

Zacks | 10 months ago
Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Zacks | 10 months ago
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.

Zacks | 10 months ago
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 10 months ago
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs

One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.

247wallst | 10 months ago
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.

Zacks | 10 months ago
The Zacks Analyst Blog Merck and AbbVie

The Zacks Analyst Blog Merck and AbbVie

Merck and AbbVie are included in this Analyst Blog.

Zacks | 10 months ago
Trump Says Pharmaceutical Tariffs Coming in Near Future

Trump Says Pharmaceutical Tariffs Coming in Near Future

President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.

Youtube | 10 months ago
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.

Zacks | 10 months ago
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.

Zacks | 10 months ago
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.

This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.

The Company spend billions to produce 100% of its key medicines for Americans in the U.S.

Barrons | 10 months ago
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 10 months ago
Loading...
Load More